Department of Ophthalmology, West China Hospital of Sichuan University, No. 37 Guoxue Xiang, Wuhou District, Chengdu, Sichuan Province, 610041, China.
Eye (Lond). 2021 Aug;35(8):2294-2301. doi: 10.1038/s41433-020-01246-7. Epub 2020 Nov 2.
To determine the clinical features and course of thyroid-associated ophthalmopathy (TAO) in a large sample of Chinese patients.
We retrospectively identified a cohort of consecutive patients diagnosed with TAO at the West China Hospital from October 1, 2009 to October 1, 2019. We analysed clinical data from 3620 patients, including demographic data, clinical manifestations, ophthalmology examinations, and prognosis.
TAO most frequently occurred with hyperthyroidism, with most patients developing TAO after thyroid disease (TD). The TAO phenotype was asymmetric in 375 (50.7%) euthyroid patients, 25 (27.8%) hypothyroid patients, and 314 (12.1%) hyperthyroid patients (p < 0.0001). The most frequent symptom was lid lag and the most commonly involved extraocular muscle was the inferior rectus. Severity assessment (NOSPECS score) and clinical activity assessment (Clinical Activity Scores, CAS) differed significantly between male and female patients (P < 0.000). The majority (88.8%) of patients had clinically inactive TAO, and only 3.2% of cases were sight-threatening. Regarding the clinical process, 75.5% of patients had an active phase time less than 12 months and 2.1% showed complete remission.
TAO most commonly develops in females and is closely related to hyperthyroidism. Euthyroid TAO often has an asymmetric clinical phenotype. CAS combined with magnetic resonance imaging can improve the detection of TAO. NOSPECS scores should be slightly refined regarding the criteria for corneal involvement. Clinical management of TAO should be individualized according to CAS or NOSPECS assessments and a multidisciplinary approach is paramount. A minority of patients showed complete remission.
在大量中国患者中确定甲状腺相关眼病(TAO)的临床特征和病程。
我们回顾性地确定了 2009 年 10 月 1 日至 2019 年 10 月 1 日期间在华西医院诊断为 TAO 的连续患者队列。我们分析了 3620 例患者的临床数据,包括人口统计学数据、临床表现、眼科检查和预后。
TAO 最常与甲状腺功能亢进症相关,大多数患者在甲状腺疾病(TD)后发生 TAO。375 例(50.7%)甲状腺功能正常患者、25 例(27.8%)甲状腺功能减退患者和 314 例(12.1%)甲状腺功能亢进患者的 TAO 表型为不对称(p<0.0001)。最常见的症状是眼睑迟滞,最常受累的眼外肌是下直肌。严重程度评估(NOSPECS 评分)和临床活动评估(临床活动评分,CAS)在男性和女性患者之间差异显著(P<0.000)。大多数(88.8%)患者的 TAO 为临床非活动期,仅有 3.2%的病例为视力威胁性。关于临床过程,75.5%的患者活动期时间小于 12 个月,2.1%的患者完全缓解。
TAO 最常见于女性,与甲状腺功能亢进症密切相关。甲状腺功能正常的 TAO 常表现为不对称的临床表型。CAS 结合磁共振成像可以提高 TAO 的检出率。NOSPECS 评分关于角膜受累的标准应略作修正。根据 CAS 或 NOSPECS 评估进行个体化的 TAO 临床管理,多学科方法至关重要。少数患者完全缓解。